Skip to main content
Top
Published in: BMC Nephrology 1/2012

Open Access 01-12-2012 | Case report

Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry disease

Authors: James O Burton, John P Dormer, Helen E Binns, Warren P Pickering

Published in: BMC Nephrology | Issue 1/2012

Login to get access

Abstract

Background

Fabry disease is an X-linked lysosomal storage disorder that results from a deficiency of the enzyme α-galactosidase A. Fabry disease is present in 4–5% of men with unexplained left ventricular hypertrophy or cryptogenic stroke. As enzyme replacement therapy is now more widely available, it is important to recognise the signs and symptoms of the disease and establish the diagnosis so that early treatment can be started before irreversible organ damage occurs.

Case Presentation

A previously fit and well 32-year-old Caucasian male presented with multisystem dysfunction including renal impairment. Although he had no suggestive symptoms, a diagnosis of Fabry disease was first established on a native renal biopsy. This was confirmed by enzymatic testing and subsequent genetic analysis that revealed a potentially new pathogenic variant.

Conclusions

This case highlights the importance both of Fabry disease as a differential diagnosis in patients with renal impairment in the context of multi-system disease and also of adequate tissue sampling for electron microscopy when performing native renal biopsies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004, 34: 236-242. 10.1111/j.1365-2362.2004.01309.x.CrossRefPubMed Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004, 34: 236-242. 10.1111/j.1365-2362.2004.01309.x.CrossRefPubMed
2.
go back to reference Sessa A, Meroni M, Battini G, Righetti M, Nebuloni M, Tosoni A, Vago GL: Evolution of renal pathology in Fabry disease. Acta paediatrica (Oslo, Norway : 1992) Supplement. 2003, 92 (443): 6-8. discussion 5 Sessa A, Meroni M, Battini G, Righetti M, Nebuloni M, Tosoni A, Vago GL: Evolution of renal pathology in Fabry disease. Acta paediatrica (Oslo, Norway : 1992) Supplement. 2003, 92 (443): 6-8. discussion 5
3.
go back to reference Gal A, Hughes DA, Winchester B: Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. J Inherit Metab Dis. 2011, 34: 509-514. 10.1007/s10545-010-9261-9.CrossRefPubMedPubMedCentral Gal A, Hughes DA, Winchester B: Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. J Inherit Metab Dis. 2011, 34: 509-514. 10.1007/s10545-010-9261-9.CrossRefPubMedPubMedCentral
4.
go back to reference Bernstein H, Bishop D, Astrin K, Komreich R, Eng C, Sakuraba H, Desnick R: Fabry disease: six gene rearrangements and an exonic point mutation in the a-galactosidase gene. J Clin Invest. 1989, 83: 1390-1399. 10.1172/JCI114027.CrossRefPubMedPubMedCentral Bernstein H, Bishop D, Astrin K, Komreich R, Eng C, Sakuraba H, Desnick R: Fabry disease: six gene rearrangements and an exonic point mutation in the a-galactosidase gene. J Clin Invest. 1989, 83: 1390-1399. 10.1172/JCI114027.CrossRefPubMedPubMedCentral
5.
go back to reference Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop D, Desnick R, Suzuki Y: Identification of point mutations in the a-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990, 47: 784-789.PubMedPubMedCentral Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop D, Desnick R, Suzuki Y: Identification of point mutations in the a-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990, 47: 784-789.PubMedPubMedCentral
6.
go back to reference Spada M, Pagliardini S, Yasuda M, Turkel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ: High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006, 79: 31-40. 10.1086/504601.CrossRefPubMedPubMedCentral Spada M, Pagliardini S, Yasuda M, Turkel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ: High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006, 79: 31-40. 10.1086/504601.CrossRefPubMedPubMedCentral
7.
go back to reference Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, et al: Results of a nationwide screening for Anderson–Fabry disease among dialysis patients. J Am Soc Nephrol. 2004, 15: 1323-1329. 10.1097/01.ASN.0000124671.61963.1E.CrossRefPubMed Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, et al: Results of a nationwide screening for Anderson–Fabry disease among dialysis patients. J Am Soc Nephrol. 2004, 15: 1323-1329. 10.1097/01.ASN.0000124671.61963.1E.CrossRefPubMed
8.
go back to reference Linthorst GE, Bouwman MG, Wijburg FA, Aerts JMFG, Poorthuis BJHM, Hollak CEM: Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010, 47 (4): 217-222. 10.1136/jmg.2009.072116.CrossRefPubMed Linthorst GE, Bouwman MG, Wijburg FA, Aerts JMFG, Poorthuis BJHM, Hollak CEM: Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010, 47 (4): 217-222. 10.1136/jmg.2009.072116.CrossRefPubMed
9.
go back to reference Branton M, Schiffmann R, Sabnis S, Murray GJ, Quirk JM, Altarescu G, Brady RO, Goldfarb L, Balow JE, Austin HAI, et al: Natural history of Fabry renal disease: Influence of a-galactosidase activity and genetic mutations on clinical course. Medicine. 2002, 81: 122-138. 10.1097/00005792-200203000-00003.CrossRefPubMed Branton M, Schiffmann R, Sabnis S, Murray GJ, Quirk JM, Altarescu G, Brady RO, Goldfarb L, Balow JE, Austin HAI, et al: Natural history of Fabry renal disease: Influence of a-galactosidase activity and genetic mutations on clinical course. Medicine. 2002, 81: 122-138. 10.1097/00005792-200203000-00003.CrossRefPubMed
10.
go back to reference MacDermot KD, Holmes A, Miners AH: Anderson–Fabry disease Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001, 38: 750-760. 10.1136/jmg.38.11.750.CrossRefPubMedPubMedCentral MacDermot KD, Holmes A, Miners AH: Anderson–Fabry disease Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001, 38: 750-760. 10.1136/jmg.38.11.750.CrossRefPubMedPubMedCentral
11.
go back to reference MacDermot KD, Holmes A, Miners AH: Anderson–Fabry disease Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001, 38: 769-775. 10.1136/jmg.38.11.769.CrossRefPubMedPubMedCentral MacDermot KD, Holmes A, Miners AH: Anderson–Fabry disease Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001, 38: 769-775. 10.1136/jmg.38.11.769.CrossRefPubMedPubMedCentral
12.
go back to reference Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassman G, Widmer U, Beck M: Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey. Acta Paediatr. 2006, 95: 86-92.CrossRefPubMed Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassman G, Widmer U, Beck M: Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey. Acta Paediatr. 2006, 95: 86-92.CrossRefPubMed
13.
go back to reference Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, et al: Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010, 25 (7): 2168-2177. 10.1093/ndt/gfp528.CrossRefPubMed Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, et al: Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2010, 25 (7): 2168-2177. 10.1093/ndt/gfp528.CrossRefPubMed
14.
go back to reference Barbey F, Lidove O, Schwarting A: Fabry nephropathy: 5 years of enzyme replacement therapy—a short review. NDT Plus. 2008, 1: 11-19. 10.1093/ndtplus/sfm022. Barbey F, Lidove O, Schwarting A: Fabry nephropathy: 5 years of enzyme replacement therapy—a short review. NDT Plus. 2008, 1: 11-19. 10.1093/ndtplus/sfm022.
15.
go back to reference Pullman JM, Ferrario F, Nast CC: Actual practices in nephropathology: a survey and comparison with best practices. Adv Anat Pathol. 2007, 14: 132-140. 10.1097/PAP.0b013e31803250d8.CrossRefPubMed Pullman JM, Ferrario F, Nast CC: Actual practices in nephropathology: a survey and comparison with best practices. Adv Anat Pathol. 2007, 14: 132-140. 10.1097/PAP.0b013e31803250d8.CrossRefPubMed
17.
go back to reference Furness PN, Boyd S: Electron microscopy and immunocytochemistry in the assessment of renal biopsy specimens: actual and optimal practice. J Clin Pathol. 1996, 49: 233-237. 10.1136/jcp.49.3.233.CrossRefPubMedPubMedCentral Furness PN, Boyd S: Electron microscopy and immunocytochemistry in the assessment of renal biopsy specimens: actual and optimal practice. J Clin Pathol. 1996, 49: 233-237. 10.1136/jcp.49.3.233.CrossRefPubMedPubMedCentral
Metadata
Title
Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry disease
Authors
James O Burton
John P Dormer
Helen E Binns
Warren P Pickering
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2012
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-13-73

Other articles of this Issue 1/2012

BMC Nephrology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine